BioNTech Analysts Keep the Faith but Trim Their Targets as Roche Picks Up the R&D Bill
Published on 11/09/2026 at 03:40 | Editorial boerse-global.de
BioNTech's third-quarter report card drew a wave of reaffirmed buy ratings this week, yet the price tags attached to them moved in the opposite direction. Bank of America Securities cut its target to $108 from $114 on Wednesday while keeping its buy recommendation, according to media reports. Morgan Stanley trimmed its own target to $106 from $114 the same day, holding its "Overweight" rating. UBS lowered its target to $125 from $135 and likewise stuck with a buy call, having issued a buy recommendation with a $125 target on November 3. Other brokerages also reduced their marks while leaving positive ratings in place.
That combination — conviction intact, valuation benchmark lowered — frames the stock's current position more tellingly than any single target figure. The shares rose 2.3% on Friday, though no link between that move and the analysts' decisions has been established.
A quarterly profit against a nine-month loss
The reassessments followed BioNTech's November 3 release of third-quarter 2026 results: revenue of EUR 1.29 billion and net profit of EUR 184.5 million. The company attributed the year-on-year revenue decline to weaker demand for COVID-19 vaccines. For the first nine months of 2026, BioNTech reported a net loss of EUR 1.17 billion. Alongside the quarterly figures, it raised the lower bound of its full-year revenue guidance and now expects EUR 1.7 billion to EUR 1.9 billion for 2026.
The profit gives the valuation a reference point already achieved, while the pipeline represents what may come. A convincing read on the stock needs both halves: delivered results anchoring the present, studies filling in the future.
Should investors sell immediately? Or is it worth buying BioNTech?
Buybacks running against a $1 billion authorization
In the mandatory disclosure filed November 3, BioNTech put shares repurchased through September 30 at EUR 403.5 million. The program permits purchases of up to $1.0 billion in total and runs until May 6, 2027. By the reporting date, roughly 5 million ADS had been bought back under the scheme.
Roche to shoulder R&D costs from 2027
Also on November 3, BioNTech said future research and development costs within its collaboration with Roche/Genentech will in principle transfer to the partner from January 1, 2027. Should the program succeed, BioNTech retains the right to royalties.
Clinical news has been more nuanced. On October 26, BioNTech and DualityBio reported a statistically significant but moderate advantage in progression-free survival for their breast cancer therapy trastuzumab pamirtecan versus chemotherapy. Overall survival data remained immature. The companies described the potential benefit in the existing treatment landscape as limited and said they would determine next steps.
BioNTech at a turning point? This analysis reveals what investors need to know now.
A separate combination — BioNTech's pumitamig with Gilead's sacituzumab govitecan — is slated for evaluation as a first-line treatment in locally advanced or metastatic triple-negative breast cancer with low or absent PD-L1 expression. The planned global Phase 3 ROSETTA Breast-01 trial is subject to regulatory approval, giving the collaboration a defined clinical framework and a clear condition for proceeding.
The tension between upheld buy ratings and reduced targets is the more useful gauge than any isolated call. Optimism from multiple houses stands as long as operational and clinical progress sustains it; the lower targets impose a more cautious financial frame around that confidence.
Ad
BioNTech Stock: New Analysis - 9 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
